Pro-inflammatory tumor profile predicts PCR in NSCLC to neoadjuvant chemoimmunotherapy
2 Views
administrator
07/30/23
Marta Casarrubios, MSc, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain, talks on an analysis into pre-treatment tumor samples of patients from the Phase II NADIM (NCT03081689) trial undergoing neoadjuvant chemoimmunotherapy. A pro-inflammatory tumor profile in the pre-treatment samples of patients with complete pathological response (CPR) was found. The pro-inflammatory tumor profile may predict an effective immune response to nivolumab. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.
Show more
Facebook Comments
No comments found